<?xml version='1.0' encoding='utf-8'?>
<document id="30012768"><sentence text="Comprehensive Substrate Characterization of 22 Antituberculosis Drugs for Multiple Solute Carrier (SLC) Uptake Transporters In Vitro." /><sentence text="The substrate potentials of antituberculosis drugs on solute carrier (SLC) transporters are not well characterized to date, despite a well-established understanding of their drug dispositions and pharmacokinetics" /><sentence text=" In this study, we investigated comprehensively the substrate potentials of the 22 currently available antituberculosis drugs for SLC family transporter-mediated uptake, using Xenopus laevis oocytes and stably transfected HEK-293 cells in vitro The result suggested that ethambutol, isoniazid, amoxicillin, and prothionamide act as novel substrates for the SLC transporters"><entity charOffset="271-281" id="DDI-PubMed.30012768.s3.e0" text="ethambutol" /><entity charOffset="283-292" id="DDI-PubMed.30012768.s3.e1" text="isoniazid" /><entity charOffset="294-305" id="DDI-PubMed.30012768.s3.e2" text="amoxicillin" /><entity charOffset="311-324" id="DDI-PubMed.30012768.s3.e3" text="prothionamide" /><pair ddi="false" e1="DDI-PubMed.30012768.s3.e0" e2="DDI-PubMed.30012768.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30012768.s3.e0" e2="DDI-PubMed.30012768.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30012768.s3.e0" e2="DDI-PubMed.30012768.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30012768.s3.e0" e2="DDI-PubMed.30012768.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30012768.s3.e1" e2="DDI-PubMed.30012768.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30012768.s3.e1" e2="DDI-PubMed.30012768.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30012768.s3.e1" e2="DDI-PubMed.30012768.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30012768.s3.e2" e2="DDI-PubMed.30012768.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30012768.s3.e2" e2="DDI-PubMed.30012768.s3.e3" /></sentence><sentence text=" In addition, in the presence of representative transporter inhibitors, the uptake of the antituberculosis drugs was markedly decreased compared with the uptake in the absence of inhibitor, suggesting involvement of the corresponding transporters" /><sentence text=" A cellular uptake study was performed, and the Km values of ethambutol were found to be 526"><entity charOffset="61-71" id="DDI-PubMed.30012768.s5.e0" text="ethambutol" /></sentence><sentence text="1 ± 15" /><sentence text="6, 212" /><sentence text="0 ± 20" /><sentence text="1, 336" /><sentence text="8 ± 20" /><sentence text="1, and 455" /><sentence text="0 ± 28 μM for organic cation transporter 1 (OCT1), OCT2, OCTN1, and OCTN2, respectively" /><sentence text=" Similarly, the Km of prothionamide was 805"><entity charOffset="22-35" id="DDI-PubMed.30012768.s13.e0" text="prothionamide" /></sentence><sentence text="8 ± 23" /><sentence text="4 μM for OCT1, while the Km values of isoniazid and amoxicillin for organic anion transporter 3 (OAT3) were 233"><entity charOffset="38-47" id="DDI-PubMed.30012768.s15.e0" text="isoniazid" /><entity charOffset="52-63" id="DDI-PubMed.30012768.s15.e1" text="amoxicillin" /><pair ddi="false" e1="DDI-PubMed.30012768.s15.e0" e2="DDI-PubMed.30012768.s15.e0" /><pair ddi="false" e1="DDI-PubMed.30012768.s15.e0" e2="DDI-PubMed.30012768.s15.e1" /></sentence><sentence text="7 ± 14" /><sentence text="1 and 161" /><sentence text="4 ± 10" /><sentence text="6 μM, respectively" /><sentence text=" The estimated in vivo drug-drug interaction indexes from in vitro transporter inhibition kinetics for verapamil, probenecid, and ibuprofen against ethambutol, prothionamide, isoniazid, and amoxicillin were found to show potential for clinical drug interactions"><entity charOffset="103-112" id="DDI-PubMed.30012768.s20.e0" text="verapamil" /><entity charOffset="114-124" id="DDI-PubMed.30012768.s20.e1" text="probenecid" /><entity charOffset="130-139" id="DDI-PubMed.30012768.s20.e2" text="ibuprofen" /><entity charOffset="148-158" id="DDI-PubMed.30012768.s20.e3" text="ethambutol" /><entity charOffset="160-173" id="DDI-PubMed.30012768.s20.e4" text="prothionamide" /><entity charOffset="175-184" id="DDI-PubMed.30012768.s20.e5" text="isoniazid" /><entity charOffset="190-201" id="DDI-PubMed.30012768.s20.e6" text="amoxicillin" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e0" e2="DDI-PubMed.30012768.s20.e0" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e0" e2="DDI-PubMed.30012768.s20.e1" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e0" e2="DDI-PubMed.30012768.s20.e2" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e0" e2="DDI-PubMed.30012768.s20.e3" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e0" e2="DDI-PubMed.30012768.s20.e4" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e0" e2="DDI-PubMed.30012768.s20.e5" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e0" e2="DDI-PubMed.30012768.s20.e6" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e1" e2="DDI-PubMed.30012768.s20.e1" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e1" e2="DDI-PubMed.30012768.s20.e2" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e1" e2="DDI-PubMed.30012768.s20.e3" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e1" e2="DDI-PubMed.30012768.s20.e4" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e1" e2="DDI-PubMed.30012768.s20.e5" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e1" e2="DDI-PubMed.30012768.s20.e6" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e2" e2="DDI-PubMed.30012768.s20.e2" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e2" e2="DDI-PubMed.30012768.s20.e3" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e2" e2="DDI-PubMed.30012768.s20.e4" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e2" e2="DDI-PubMed.30012768.s20.e5" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e2" e2="DDI-PubMed.30012768.s20.e6" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e3" e2="DDI-PubMed.30012768.s20.e3" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e3" e2="DDI-PubMed.30012768.s20.e4" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e3" e2="DDI-PubMed.30012768.s20.e5" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e3" e2="DDI-PubMed.30012768.s20.e6" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e4" e2="DDI-PubMed.30012768.s20.e4" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e4" e2="DDI-PubMed.30012768.s20.e5" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e4" e2="DDI-PubMed.30012768.s20.e6" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e5" e2="DDI-PubMed.30012768.s20.e5" /><pair ddi="false" e1="DDI-PubMed.30012768.s20.e5" e2="DDI-PubMed.30012768.s20.e6" /></sentence><sentence text=" In conclusion, this is the first study that demonstrated 22 antituberculosis drug interactions with transporters" /><sentence text=" This study will be helpful for mechanistic understanding of the disposition, drug-drug interactions, and pharmacokinetics of these antituberculosis drugs" /><sentence text="" /></document>